BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 19176057)

  • 1. NPM-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation.
    Pawlicki JM; Cookmeyer DL; Maseda D; Everett JK; Wei F; Kong H; Zhang Q; Wang HY; Tobias JW; Walter DM; Zullo KM; Javaid S; Watkins A; Wasik MA; Bushman FD; Riley JL
    Cancer Res; 2021 Jun; 81(12):3241-3254. PubMed ID: 33619116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alphav integrin expression and up-regulating apoptosis signaling.
    Yang Z; Lei Z; Li B; Zhou Y; Zhang GM; Feng ZH; Zhang B; Shen GX; Huang B
    Cancer Sci; 2010 Feb; 101(2):494-500. PubMed ID: 19922502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.
    Sin SH; Roy D; Wang L; Staudt MR; Fakhari FD; Patel DD; Henry D; Harrington WJ; Damania BA; Dittmer DP
    Blood; 2007 Mar; 109(5):2165-73. PubMed ID: 17082322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma.
    Lee SC; Marzec M; Liu X; Wehrli S; Kantekure K; Ragunath PN; Nelson DS; Delikatny EJ; Glickson JD; Wasik MA
    NMR Biomed; 2013 Jan; 26(1):106-14. PubMed ID: 22711601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
    Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
    Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma].
    Li JF; Li GD; Gu L; Liu WP; Li FY; Liao DY; Ma ZG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):649-53. PubMed ID: 19176054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blockage of mTOR signaling pathway by rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains].
    Gu L; Li JF; Gao J; Zhu YP; Li Q; Jia CS; Zhou CY; Ma ZG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):662-6. PubMed ID: 19176057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Common corruption of the mTOR signaling network in human tumors.
    Menon S; Manning BD
    Oncogene; 2008 Dec; 27 Suppl 2(0 2):S43-51. PubMed ID: 19956179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR signaling in glioblastoma: lessons learned from bench to bedside.
    Akhavan D; Cloughesy TF; Mischel PS
    Neuro Oncol; 2010 Aug; 12(8):882-9. PubMed ID: 20472883
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.